Deferred Tax Assets, Valuation Allowance of Monopar Therapeutics from 31 Dec 2016 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Monopar Therapeutics quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2016 to 31 Dec 2024.
  • Monopar Therapeutics Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $17,871,635, a 35% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Monopar Therapeutics Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $17,871,635 +$4,605,771 +35% 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q4 2023 $13,265,864 +$2,124,269 +19% 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q4 2022 $11,141,595 +$3,421,311 +44% 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q4 2021 $7,720,284 +$2,500,118 +48% 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q4 2020 $5,220,166 +$2,652,235 +103% 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q4 2019 $2,567,931 +$877,120 +52% 31 Dec 2019 10-K 25 Mar 2021 2020 FY
Q4 2018 $1,690,811 +$689,824 +69% 31 Dec 2018 10-K 27 Mar 2020 2019 FY
Q4 2017 $1,000,987 +$465,733 +87% 31 Dec 2017 10-K 26 Feb 2019 2018 FY
Q4 2016 $535,254 31 Dec 2016 10-K 26 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.